PTCD1

Summary

PTCD1 (pentatricopeptide repeat domain 1, HGNC:22198) is a protein-coding gene on chromosome 7q22.1, encoding Pentatricopeptide repeat-containing protein 1, mitochondrial (O75127). Mitochondrial protein implicated in negative regulation of leucine tRNA levels, as well as negative regulation of mitochondria-encoded proteins and COX activity. It is a selective cancer dependency (DepMap: 29.3% of cell lines).

This gene encodes a mitochondrial protein that binds leucine tRNAs and other mitochondrial RNAs and plays a role in the regulation of translation. Increased expression of this gene results in decreased mitochondrial leucine tRNA levels. Naturally occurring read-through transcription exists between upstream ATP5J2 (ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2) and this gene.

Source: NCBI Gene 26024 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cardiomyopathy (Limited, GenCC)
• GWAS associations: 5
• Cancer dependency (DepMap): dependent in 29.3% of screened cell lines
• MANE Select transcript: NM_015545

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22198
Approved symbol	PTCD1
Name	pentatricopeptide repeat domain 1
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0632
Ensembl gene	ENSG00000106246
Ensembl biotype	protein_coding
OMIM	614774
Entrez	26024

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000292478, ENST00000419981, ENST00000430029, ENST00000430982, ENST00000485746, ENST00000910799, ENST00000910800, ENST00000910801, ENST00000926564, ENST00000926565, ENST00000926566, ENST00000926567, ENST00000926568, ENST00000926569, ENST00000926570, ENST00000966185

RefSeq mRNA: 1 — MANE Select: NM_015545 NM_015545

CCDS: CCDS34691

Canonical transcript exons

ENST00000292478 — 8 exons

Exon	Start	End
ENSE00001839415	99438692	99438798
ENSE00001958361	99416739	99420149
ENSE00003491490	99429103	99429204
ENSE00003508384	99433278	99433418
ENSE00003528896	99423775	99423957
ENSE00003615083	99429588	99429806
ENSE00003649149	99424795	99425616
ENSE00003674826	99434790	99435268

Expression profiles

Bgee: expression breadth ubiquitous, 273 present calls, max score 96.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 206.6924 / max 2797.7887, expressed in 1828 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
85107	206.6924	1828
85103	4.3517	1634

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	96.32	gold quality
tendon of biceps brachii	UBERON:0008188	91.30	gold quality
parotid gland	UBERON:0001831	90.93	gold quality
cervix squamous epithelium	UBERON:0006922	89.72	silver quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	87.61	gold quality
olfactory bulb	UBERON:0002264	86.83	gold quality
gluteal muscle	UBERON:0002000	86.75	gold quality
diaphragm	UBERON:0001103	86.66	gold quality
biceps brachii	UBERON:0001507	86.27	gold quality
gingival epithelium	UBERON:0001949	85.98	gold quality
endothelial cell	CL:0000115	85.97	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	85.31	gold quality
vastus lateralis	UBERON:0001379	84.94	silver quality
middle temporal gyrus	UBERON:0002771	84.84	gold quality
oviduct epithelium	UBERON:0004804	84.80	silver quality
hair follicle	UBERON:0002073	84.42	gold quality
squamous epithelium	UBERON:0006914	84.19	silver quality
quadriceps femoris	UBERON:0001377	84.16	silver quality
cervix epithelium	UBERON:0004801	83.75	silver quality
heart right ventricle	UBERON:0002080	83.64	silver quality
type B pancreatic cell	CL:0000169	83.59	gold quality
gingiva	UBERON:0001828	83.47	gold quality
tongue squamous epithelium	UBERON:0006919	83.44	silver quality
pancreatic ductal cell	CL:0002079	83.43	silver quality
body of tongue	UBERON:0011876	83.17	gold quality
CA1 field of hippocampus	UBERON:0003881	83.13	silver quality
superficial temporal artery	UBERON:0001614	82.92	silver quality
thymus	UBERON:0002370	82.78	silver quality
epithelium of esophagus	UBERON:0001976	82.73	gold quality
Brodmann (1909) area 23	UBERON:0013554	82.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

75 targeting PTCD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-149-5P	99.25	67.16	1315

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 29.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• ELAC2 and PTCD1 affect the 3’ end processing of tRNAs. (PMID:21857155)
• Leucine starvation decreased PTCD1 on the protein level. (PMID:24710704)
• reduced PTCD1 activity disrupts neuronal energy homeostasis and dampens spontaneous neural transmission in Alzheimer’s Disease (PMID:30948477)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptcd1	ENSDARG00000076176
mus_musculus	Ptcd1	ENSMUSG00000029624
rattus_norvegicus	Ptcd1	ENSRNOG00000000987

Paralogs (1): OGFOD2 (ENSG00000111325)

Protein

Protein identifiers

Pentatricopeptide repeat-containing protein 1, mitochondrial — O75127 (reviewed: O75127)

All UniProt accessions (5): O75127, A4D273, C9JGL8, C9JQN9, C9JWL7

UniProt curated annotations — full annotation on UniProt →

Function. Mitochondrial protein implicated in negative regulation of leucine tRNA levels, as well as negative regulation of mitochondria-encoded proteins and COX activity. Also affects the 3’-processing of mitochondrial tRNAs.

Subunit / interactions. Associates with mitochondrial leucine tRNAs. Interacts with ELAC2.

Subcellular location. Mitochondrion. Mitochondrion matrix.

Tissue specificity. Abundant in testes, skeletal muscle and heart.

Similarity. Belongs to the PTCD1 family.

RefSeq proteins (1): NP_056360* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002885	PPR_rpt	Repeat
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR033443	PROP1-like_PPR_dom	Domain

Pfam: PF13812, PF17177

UniProt features (19 total): repeat 9, region of interest 3, compositionally biased region 3, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75127-F1	68.41	0.31

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, WANG_CLIM2_TARGETS_UP, GOBP_TRNA_METABOLIC_PROCESS, GOBP_RNA_MODIFICATION, GOBP_MITOCHONDRIAL_RNA_METABOLIC_PROCESS, MODULE_397, GOBP_TRNA_PROCESSING, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOCC_MITOCHONDRIAL_MATRIX, GOMF_TRNA_BINDING, GOMF_RRNA_BINDING, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, BRUINS_UVC_RESPONSE_MIDDLE, GOBP_TRNA_3_END_PROCESSING, GOBP_MITOCHONDRIAL_RNA_MODIFICATION

GO Biological Process (3): mitochondrial translation (GO:0032543), tRNA 3’-end processing (GO:0042780), tRNA processing (GO:0008033)

GO Molecular Function (3): tRNA binding (GO:0000049), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (2): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mitochondrion	2
translation	1
mitochondrial gene expression	1
tRNA processing	1
RNA 3’-end processing	1
RNA processing	1
tRNA metabolic process	1
RNA binding	1
nucleic acid binding	1
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1855 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTCD1	FASTKD3	Q14CZ7	802
PTCD1	NGRN	Q9NPE2	761
PTCD1	PTCD2	Q8WV60	736
PTCD1	RPUSD4	Q96CM3	729
PTCD1	FASTKD2	Q9NYY8	729
PTCD1	RPUSD3	Q6P087	728
PTCD1	PTCD3	Q96EY7	724
PTCD1	PRORP	O15091	704
PTCD1	LRPPRC	P42704	685
PTCD1	TRMT10C	Q7L0Y3	638
PTCD1	MALSU1	Q96EH3	633
PTCD1	MTERF3	Q96E29	632
PTCD1	MRPS27	Q92552	632
PTCD1	POLRMT	O00411	629
PTCD1	TRUB2	O95900	616

IntAct

177 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
FAM120A	SYNCRIP	psi-mi:“MI:0914”(association)	0.640
	DDX3X	psi-mi:“MI:0914”(association)	0.630
PTCD1	GEMIN4	psi-mi:“MI:0915”(physical association)	0.560
PTCD1	TFIP11	psi-mi:“MI:0915”(physical association)	0.560
PTCD1	CARD10	psi-mi:“MI:0915”(physical association)	0.560
PTCD1	FKBP7	psi-mi:“MI:0915”(physical association)	0.560
PTCD1	SYP	psi-mi:“MI:0915”(physical association)	0.560
PTCD1	NFKBID	psi-mi:“MI:0915”(physical association)	0.560
PTCD1	MTUS2	psi-mi:“MI:0915”(physical association)	0.560
NP	KPNA6	psi-mi:“MI:0914”(association)	0.550
MRPL50	GTPBP10	psi-mi:“MI:0914”(association)	0.530
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
RPL6	MRPS14	psi-mi:“MI:0914”(association)	0.530
RBMX	PTCD1	psi-mi:“MI:0914”(association)	0.530
DDX28	PTCD1	psi-mi:“MI:0914”(association)	0.530
MRPL2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
FBXW11	AHCYL1	psi-mi:“MI:0914”(association)	0.530
HNRNPA1	PTCD1	psi-mi:“MI:0914”(association)	0.530
IGF2BP3	PTCD1	psi-mi:“MI:0914”(association)	0.530
MRPL13	GTPBP10	psi-mi:“MI:0914”(association)	0.530
ILF2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
RPS2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530

BioGRID (173): PTCD1 (Affinity Capture-RNA), PTCD1 (Affinity Capture-RNA), PTCD1 (Affinity Capture-RNA), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS), PTCD1 (Affinity Capture-MS)

ESM2 similar proteins: A2VD13, A6QP29, A7E3N7, B5DFG1, O75127, P54098, P54099, Q05AA6, Q13474, Q3SX05, Q3SZK4, Q3TYG6, Q3U0L2, Q3U5Q7, Q3URY6, Q3ZBK7, Q4R5Q4, Q53GS7, Q58CQ5, Q5R655, Q5RAS2, Q66H85, Q6NUQ4, Q6ZUX3, Q7YS91, Q80UU1, Q8BKF1, Q8BL74, Q8C0R7, Q8C1F5, Q8C2E4, Q8CJ00, Q8N4P6, Q8R322, Q8TE82, Q969Z0, Q96KN7, Q96MK2, Q99MQ3, Q9BQ95

Diamond homologs: A2VD13, O75127, Q5R655, Q8C2E4, Q9SVP7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 144 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Mitochondrial ribosome-associated quality control	22	27.6×	7e-24
Mitochondrial translation initiation	19	24.6×	9e-20
Mitochondrial translation elongation	19	24.6×	9e-20
Mitochondrial translation	17	23.9×	2e-17
Transport of Mature Transcript to Cytoplasm	6	23.3×	4e-06
Mitochondrial translation termination	19	21.3×	1e-18
RNA Polymerase II Transcription Termination	6	13.4×	1e-04
Processing of Capped Intron-Containing Pre-mRNA	15	12.6×	3e-11

GO biological processes:

GO term	Partners	Fold	FDR
mitochondrial large ribosomal subunit assembly	8	62.4×	5e-11
positive regulation of mitochondrial translation	5	44.2×	6e-06
positive regulation of cytoplasmic translation	5	39.0×	9e-06
negative regulation of mRNA splicing, via spliceosome	5	30.2×	3e-05
mitochondrial translation	21	28.7×	2e-22
regulation of alternative mRNA splicing, via spliceosome	9	17.3×	3e-07
RNA processing	8	13.8×	9e-06
negative regulation of translation	7	10.8×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

5163 predictions. Top by Δscore:

Variant	Effect	Δscore
7:99417423:T:A	acceptor_gain	1.0000
7:99417425:ACAG:A	acceptor_loss	1.0000
7:99417426:CAGA:C	acceptor_loss	1.0000
7:99417427:A:AG	acceptor_gain	1.0000
7:99417428:G:GG	acceptor_gain	1.0000
7:99417428:GA:G	acceptor_gain	1.0000
7:99417428:GAA:G	acceptor_gain	1.0000
7:99417428:GAAC:G	acceptor_gain	1.0000
7:99417428:GAACT:G	acceptor_gain	1.0000
7:99417583:C:T	donor_gain	1.0000
7:99417590:G:GT	donor_gain	1.0000
7:99417590:G:T	donor_gain	1.0000
7:99417592:AGTG:A	donor_loss	1.0000
7:99417593:GTG:G	donor_gain	1.0000
7:99417593:GTGGT:G	donor_loss	1.0000
7:99417595:GGTA:G	donor_loss	1.0000
7:99417596:G:GA	donor_loss	1.0000
7:99417597:T:C	donor_loss	1.0000
7:99417615:C:G	donor_gain	1.0000
7:99420150:C:CC	acceptor_gain	1.0000
7:99423795:A:AC	donor_gain	1.0000
7:99423796:C:CC	donor_gain	1.0000
7:99423796:CTGGG:C	donor_gain	1.0000
7:99423830:T:TA	donor_gain	1.0000
7:99424790:CTCA:C	donor_loss	1.0000
7:99424791:TCA:T	donor_loss	1.0000
7:99424792:CACCT:C	donor_loss	1.0000
7:99424793:A:AT	donor_loss	1.0000
7:99424794:C:CT	donor_loss	1.0000
7:99425613:ACACC:A	acceptor_loss	1.0000

AlphaMissense

4558 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:99420089:A:G	W661R	0.995
7:99420089:A:T	W661R	0.995
7:99420109:A:G	F654S	0.994
7:99420108:G:C	F654L	0.993
7:99420108:G:T	F654L	0.993
7:99420110:A:G	F654L	0.993
7:99433347:G:C	N175K	0.992
7:99433347:G:T	N175K	0.992
7:99420106:C:G	R655P	0.991
7:99423812:A:G	L628P	0.988
7:99433288:A:G	L195P	0.988
7:99424847:G:T	A562D	0.986
7:99433325:A:G	C183R	0.986
7:99420087:C:A	W661C	0.985
7:99420087:C:G	W661C	0.985
7:99433384:A:G	M163T	0.985
7:99429757:A:G	F215S	0.984
7:99433336:A:T	L179Q	0.984
7:99429700:A:G	L234P	0.983
7:99429749:A:G	C218R	0.983
7:99429760:A:G	L214P	0.983
7:99434816:A:G	C143R	0.983
7:99424811:A:G	L574P	0.982
7:99429760:A:T	L214Q	0.982
7:99433336:A:C	L179R	0.982
7:99433409:C:G	A155P	0.982
7:99424848:C:G	A562P	0.981
7:99429640:A:G	L254P	0.981
7:99420098:A:C	Y658D	0.980
7:99420085:A:G	L662P	0.979

dbSNP variants (sampled 300 via entrez): RS1000026358 (7:99416421 T>C,G), RS1000236639 (7:99440373 CAG>C), RS1000426419 (7:99428196 G>A), RS1000565565 (7:99433527 G>A), RS1000581513 (7:99433121 C>T), RS1000597971 (7:99433763 C>G), RS1000661242 (7:99426192 C>T), RS1000711537 (7:99438279 C>T), RS1001187819 (7:99438586 C>A,T), RS1001362260 (7:99417983 C>G,T), RS1001412116 (7:99422210 C>T), RS1001426958 (7:99419279 T>C), RS1001435506 (7:99417746 A>G), RS1001584593 (7:99422939 T>C), RS1001665265 (7:99423113 G>A)

Disease associations

OMIM: gene MIM:614774 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
cardiomyopathy	Limited	Autosomal recessive

Mondo (1): cardiomyopathy (MONDO:0004994)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004730_2	Facial emotion recognition (sad faces)	3.000000e-06
GCST005144_1	Tacrolimus trough concentration in kidney transplant patients	2.000000e-17
GCST010988_163	Adult body size	7.000000e-15
GCST90002389_160	Lymphocyte percentage of white cells	4.000000e-16
GCST90002399_184	Neutrophil percentage of white cells	2.000000e-15

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0008329	facial emotion recognition measurement
EFO:0008458	tacrolimus measurement
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009202	Cardiomyopathies	C14.280.238

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	increases expression	1
tetrabromobisphenol A	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
Cisplatin	decreases expression	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Urethane	increases expression	1
Valproic Acid	increases methylation	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00170183	PHASE3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	PHASE3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	PHASE3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	PHASE3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	PHASE3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	PHASE3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	PHASE3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	PHASE3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	PHASE3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	PHASE3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	PHASE3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	PHASE3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	PHASE3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	PHASE3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
NCT07116473	PHASE3	NOT_YET_RECRUITING	To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT00185250	PHASE2	COMPLETED	Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
NCT00490347	PHASE2	COMPLETED	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
NCT00694161	PHASE2	COMPLETED	The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy